P2-083 - Oxaliplatin-Induced Hypersensitivity Reactions in Patients with Advanced Colorectal Cancer in a Single Hospital

Abstract

ABSTRACT Oxaliplatin is a third-generation platinum agent indicated for the treatment of colorectal cancer. It is regarded as a high risk for the development of hypersensitivity reactions. Clinical date from 119 patients with colorectal cancer were analyzed, who were treated with oxaliplatin containing regimens (FOLFOX4, mFOLOX6, Xelox, SOX) between April 2007 and January 2012. Eight males and nine females had hypersensitivity reactions. The 17 patients were 43–75 years (median 63 years), total cycle number of therapy with oxaliplatin were 2–19 cycles (median 9 cycles). The severity of hypersensitivity reactions was assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Five cases had grade 1, 11 cases grade 2 and 1 case had grade 3 hypersensitivity reactions. An immediate hypersensitivity reaction showed itching, rash, stomachache, vomit and choking. Oxygen saturation was measured continuously. Hypoxemia was diagnosed for patients and they were given oxygen. The oxaliplatin infusion was withheld and substituted with fluid support. Chlorpheniramine maleate and mPSL were administered to alleviate the hypersensitivity reactions. There was no mortality, and no one required intensive care. One case could resume chemotherapy with oxaliplatin by strong pretreatment. On the basis of our experience, we consider the hypersensitivity reactions to oxialiplatin, essential medications for the hypersensitivity reactions and the course in our hospital that we can try to treat with oxaliplatin again.